key: cord-0796097-cpy1zbpl
authors: Docherty, Kieran F.; McMurray, John J.V.
title: SOLOIST‐WHF and updated meta‐analysis: sodium–glucose co‐transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure
date: 2020-12-29
journal: Eur J Heart Fail
DOI: 10.1002/ejhf.2075
sha: c92ce1afa48e439eb27daec3a8e7a27dec89db92
doc_id: 796097
cord_uid: cpy1zbpl

nan

Sotagliflozin is a dual inhibitor of sodium-glucose co-transporter (SGLT) 1 and 2, although it is approximately 20-fold more selective for SGLT2. 1 SGLT1 contributes to glucose reabsorption in the gastrointestinal tract, whereas SGLT2 has this function in the proximal renal tubule. 2 The effects of sotagliflozin in heart failure were recently studied in the Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure trial (SOLOIST-WHF). 3 SOLOIST-WHF had a complex history including withdrawal of the major sponsor, a resulting shortfall in funding and the impact of the novel coronavirus disease pandemic. As a result, fewer patients were recruited than originally intended (1222 instead of 4000), the trial was terminated early, potential endpoints were not fully adjudicated, and the primary outcome was changed from that originally planned (first occurrence of either hospitalization for heart failure or cardiovascular death). Despite these tribulations, the investigators are to be congratulated in maintaining the integrity of the trial, bringing it to successful completion, and promptly analysing and reporting their findings. As a result, SOLOIST-WHF fills an important gap in knowledge about the use of SGLT2 inhibitors to treat patients with heart failure and reduced ejection fraction (HFrEF) and offers a tantalising suggestion that these drugs may also be beneficial in patients with heart failure and preserved ejection fraction (HFpEF). 3 Unlike the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction trial (EMPEROR-Reduced) and the Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF), SOLOIST-WHF enrolled patients with worsening of existing heart failure requiring intravenous diuretic therapy, usually in the hospital setting (the proportion enrolled out of hospital has not been reported). 4, 5 At randomization, participants were required to have a B-type natriuretic peptide (BNP) level ≥150 pg/mL (≥450 pg/mL for patients with atrial fibrillation) or N-terminal proBNP (NT-proBNP) ≥600 pg/mL (≥1800 pg/mL for patients * 

with atrial fibrillation). 3 There was no upper left ventricular ejection fraction (LVEF) limit, but randomization was stratified according to LVEF (<50% or ≥50%). Unlike DAPA-HF and EMPEROR-Reduced, patients were required to have a diagnosis of type 2 diabetes. [3] [4] [5] [6] [7] [8] Patients were randomized when haemodynamically stable, prior to hospital discharge (n = 596) or within 3 days after discharge (n = 626). Key exclusion criteria were systolic blood pressure <100 mmHg, estimated glomerular filtration rate <30 mL/min/1.73 m 2 and a digoxin level >1.2 ng/mL. The revised primary endpoint was total number of hospitalizations and urgent visits for heart failure (first and subsequent) and deaths from cardiovascular causes. 3 Not surprisingly, patients enrolled in SOLOIST-WHF differed in several ways from those in DAPA-HF and EMPEROR-Reduced ( Table 1) . [3] [4] [5] [6] [7] [8] They were older and more were women and the median LVEF was higher (all in keeping with the absence of an upper LVEF threshold for inclusion); the median estimated glomerular filtration rate was lower (in keeping with the greater proportion of older people and women and requirement for all patients to have type 2 diabetes). Because all patients had recent worsening heart failure, the proportion remaining in New York Heart Association class III and IV was greater than in the earlier trials and median NT-proBNP was higher than in DAPA-HF (although not EMPEROR-Reduced, reflecting the inclusion criteria for that trial). [3] [4] [5] [6] [7] [8] The findings of SOLOIST-WHF are difficult to compare directly with DAPA-HF and EMPEROR-Reduced because of the different patient population enrolled, characteristics of the drug and the use of unadjudicated events. Hospitalized patients have higher event rates than ambulatory patients and participants with type 2 diabetes higher rates than those without diabetes. The adjudication process usually rejects a substantial proportion of suspected worsening heart failure events, so use of unadjudicated events also inflates the endpoint rate. 9 The single outcome not influenced by adjudication is all-cause mortality and the rate of death from any cause in the placebo group of SOLOIST-WHF was 16.3 per 100 person-years of follow-up, much higher than the rates of 9.5 and 10.7 per 100 person-years in DAPA-HF and EMPEROR-Reduced, respectively. Although not the final, revised, primary outcome, the SOLOIST-WHF investigators did report time to first occurrence of hospitalization for worsening heart failure or death from cardiovascular causes, which was the primary endpoint in EMPEROR-Reduced and the first secondary endpoint in DAPA-HF. The hazard ratio for this outcome was 0.71 [95% confidence interval (CI) 0.56-0.89] in SOLOIST-WHF, compared with 0.75 (0.65-0.86) in EMPEROR-Reduced and 0.75 (0.65-0.85) in DAPA-HF. [3] [4] [5] 10 This one outcome that can be compared across all three trials demonstrates remarkable consistency of benefit, despite the differences in populations enrolled. In SOLOIST-WHF, the hazard ratio for the revised primary endpoint, total number of hospitalizations and urgent visits for heart failure (first and subsequent) and deaths from cardiovascular causes, was 0.67 results of all three trials are pooled, there is a clear reduction in both cardiovascular and all-cause mortality (Figure 1) .

The key subgroups of interest were LVEF <50% vs. ≥50% and treatment initiation before or after discharge from hospital, each of which showed a benefit consistent with that in the trial overall. Clearly, the LVEF subgroup is particularly notable as it hints at efficacy in HFpEF similar to that in HFrEF, although the number of patients with a LVEF ≥50% was modest (n = 256). In an additional LVEF subgroup analysis, the hazard ratio for the primary outcome was 0.69 (0.51-0.92) in patients with a LVEF <40% (n = 725) and 0.68 (0.45-1.03) in patients with a LVEF ≥40% (n = 494).

The analysis of safety was also crucial, especially as the patients studied were enrolled either in hospital or shortly after discharge. Concerns have been raised about administration of SGLT2 inhibitors in hospitalized patients and the risk of diabetic ketoacidosis. 11, 12 Despite all patients in SOLOIST-WHF having type 2 diabetes, in the safety analysis only 2 of 605 patients in the sotagliflozin group experienced diabetic ketoacidosis compared with 4 of 611 patients in the placebo group. Of interest, significantly more patients in the sotagliflozin group (n = 42) experienced diarrhoea than in the placebo group (n = 25), a difference not reported in DAPA-HF or EMPEROR-Reduced and one likely to reflect SGLT1 inhibition in the intestines.

In summary, SOLOIST-WHF contributes three very important findings relevant to the use of SGLT2 inhibitors in clinical practice. First, it adds a third trial confirming the benefits of drugs in this class for patients with HFrEF, creating a particularly strong evidence base (Figure 1) . Second, SOLOIST-WHF answers the question about whether this treatment can be started in hospital following an episode of decompensation (and the answer is resoundingly yes). Third, SOLOIST-WHF shows that use of a SGLT2 inhibitor in patients stabilized after an episode of decompensation is not associated with an increased risk of diabetic ketoacidosis. Here it is worth specifying how 'stabilized' was defined in the trial: a systolic blood pressure ≥100 mmHg, no treatment with intravenous inotropic therapy or intravenous vasodilators within 2 days prior to randomization, and no requirement for mechanical ventilation or oxygen therapy in the last 24 h. Patients also had to have discontinued intravenous diuretic and chronic oral loop diuretic prescribed and/or administered. Patients with diabetes, especially those on insulin, or an insulin secretagogue, may still be at risk of diabetic ketoacidosis if fluid and calorie intake is curtailed, insulin dose reduced, or both. 11, 12 Finally, as alluded to earlier, SOLOIST-WHF offers the first tantalising hint that SGLT2 inhibitors might also be beneficial in HFpEF, although we need to wait until later in 2021-22 for definitive proof, which will be provided by the two large ongoing dedicated HFpEF trials, i.e. EMPEROR-Preserved (NCT03057951) and the Dapagliflozin Evaluation to improve the LIVEs of patients with pReserved ejection fraction heart failure (DELIVER, NCT03619213). Importantly, DELIVER also includes hospitalized and recently discharged patients, as in SOLOIST-WHF. While waiting for the results of EMPEROR-Preserved and DELIVER, the immediate priority for physicians is to implement this highly effective (and cost-effective) treatment in patients with HFrEF, the majority of whom are eligible for it. 13 

Sotagliflozin: a review in type 1 diabetes

Sodium-glucose co-transporters and their inhibition: clinical physiology

SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure

DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction

EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

DAPA-HF Committees and Investigators. The Dapagliflozin and Prevention of Adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics

Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial

Do we need clinical events committees to adjudicate end points?

SGLT2 inhibitors in patients with heart

failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors and ketogenesis: the good and the bad

Diabetic ketoacidosis with SGLT2 inhibitors

Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF

Applicability of US Food and Drug Administration labeling for dapagliflozin to patients with heart failure with reduced ejection fraction in US clinical practice: the Get With the Guidelines-Heart Failure (GWTG-HF) registry